Hematologic Cancers

Using the recommended dose of 1.3 mg/m2administered as a 3- to 5-second bolus intravenous (IV) injection on days 1, 4, 8, and 11 of 21-day cycles, patients with relapsed multiple myeloma (MM) after 1 to 3 previous lines of therapy achieved noninferior efficacy with subcutaneous versus IV delivery of the drug when receiving up to eight 21-day cycles. In addition, those in the SQ arm experienced improvement in their systemic safety profile.


Read More ›

Multiple myeloma (MM) is a disease with variable presentation, disease trajectory, prognosis, and options for treatment. Integrating the plethora of scientific discovery relative to plasma cell disorders, molecular and cytogenetic attributes and their implications for prognosis and treatment, identification of key components of the bone marrow micro - environment, and the development of novel therapies targeting many of these attributes requires a thorough review of multiple sources of information. Multiple Myeloma: A Textbook for Nurses, edited by Joseph D. Read More ›

The addition of new biomarkers for establishing a prognosis for patients with breast cancer has been recommended in the 2010 edition of the American Joint Committee of Cancer’s Cancer Staging Handbook.1 Human epidermal growth factor receptor type 2 (HER2) status and multigene signature “scores” have been added to estrogen receptor (ER) and progesterone receptor (PR) determinations.1 So, where are we regarding multigene signature scores? Read More ›

Aresearch-based educational program aimed at enhancing communication between non-Hodgkin lymphoma patients and their healthcare providers has just been launched and is available for healthcare providers.

Framing Life With Lymphoma was developed by the Cancer Support Community, which unites The Wellness Community and Gilda’s Club World wide, and was supported by a grant from Cephalon.

Read More ›

Women who have difficulty performing normal activities of daily living after an initial treatment for breast cancer have reduced overall survival compared with survivors without functional limitations, results of a long-term study indicate.
“Our study provides evidence of why it is important to develop interventions that improve physical function, to mitigate the adverse effects of physical limitations,” said lead author Dejana Braithwaite, PhD, of the University of California San Francisco.

CHICAGO—Among patients with chronic myeloid leukemia (CML) in the Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed Patients (ENESTnd) study, major molecular response (MMR) rates with nilotinib remain superior to those with imatinib after follow-up extended to a median of 18.5 months. Read More ›

The evolving epidemiology statistics relative to breast cancer world wide are alarming. The cumulative incidence of breast cancer is 6.3% in developed countries compared with 1.0% in undeveloped countries. Western developed areas show increasing rates, with projections of 2 million cases diagnosed annually.

Advances in understanding of the causes of breast cancer, epidemiology, risk factors, and both maturing data and new findings on hormonal, cytotoxic, and biological approaches were presented at the 32nd annual San Antonio Breast Cancer Symposium.

Read More ›

Multiple myeloma (MM), although currently incurable, has seen significantly improved response and overall survival (OS) rates with the inclusion of targeted therapy in its treatment schema. MM therapy has evolved greatly over the past several years and, with innovative research and medications, this disease may soon be curable. This article will focus on the novel agents revolutionizing therapy of MM.

Read More ›

In the first head-to-head comparison of targeted oral tyrosine kinase inhibitors as initial treatment for early-stage chronic myeloid leukemia (CML), molecular and cytogenetic remissions were more common with nilotinib compared with imatinib, the previous standard for treating early-stage CML, said Giuseppe Saglio, MD.

Read More ›

Page 9 of 10

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: